Advertisement
Canada markets open in 5 hours 11 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7312
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    83.17
    +0.36 (+0.43%)
     
  • Bitcoin CAD

    87,718.12
    -3,250.41 (-3.57%)
     
  • CMC Crypto 200

    1,333.13
    -49.44 (-3.58%)
     
  • GOLD FUTURES

    2,340.60
    +2.20 (+0.09%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,477.75
    -186.75 (-1.06%)
     
  • VOLATILITY

    16.20
    +0.23 (+1.44%)
     
  • FTSE

    8,077.51
    +37.13 (+0.46%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6815
    -0.0004 (-0.06%)
     

Analysts’ Recommendations for Akcea and Its Peers in March

Analysts’ Recommendations for Akcea and Its Peers in March

Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.